Skip to main content

Advertisement

SpringerLink
Log in

Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Acromegaly is a rare disease due to growth hormone (GH)-secreting pituitary adenoma. GH and IGF-1 levels are usually congruent, indicating either remission or active disease; however, a discrepancy between GH and IGF-1 may occur. We aimed to evaluate the outcome of diabetes mellitus (DM) and hypertension (HT) in acromegalic patients with congruent GH and/or IGF-1 levels vs. discordant biochemical parameters.

Methods

Retrospective analysis of the data of 3173 patients from the Liege Acromegaly Survey (LAS) allowed us to include 190 patients from 8 tertiary referral centers across Europe, treated by surgery, with available data concerning DM and HT both at diagnosis and at the last follow-up (LFU). We recorded the number of anti-HT and anti-DM drugs used at the first evaluation and at LFU for every patient.

Results

Ninety-nine patients belonged to the REM group (concordant parameters), 65 patients were considered as GHdis (high random GH/controlled IGF-1), and 26 patients were considered as IGF-1dis (high IGF-1/controlled random GH). At diagnosis, 72 patients (37.8%) had HT and 54 patients had DM (28.4%). There was no statistically significant difference in terms of the number of anti-HT and anti-DM drugs at diagnosis versus LFU (mean duration: 7.3 ± 4.5 years) between all three groups.

Conclusion

The long-term outcome of DM and HT in acromegaly does not tend to be more severe in patients with biochemical discordance in comparison with patients considered as in remission on the basis of concordant biological parameters, suggesting that patients with biochemical discordance do not require a closer follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. A. Colao, L.F.S. Grasso, A. Giustina, S. Melmed, P. Chanson, A.M. Pereira, R. Pivonello, Acromegaly. Nat. Rev. Dis. Prim. 5, 20 (2019)

    Article  Google Scholar 

  2. M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40, 268 (2019)

    Article  Google Scholar 

  3. A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski, M. Bolanowski, V. Bonert, M.D. Bronstein, F.F. Casanueva, D. Clemmons, A. Colao, D. Ferone, M. Fleseriu, S. Frara, M.R. Gadelha, E. Ghigo, M. Gurnell, A.P. Heaney, K. Ho, A. Ioachimescu, L. Katznelson, F. Kelestimur, J. Kopchick, M. Krsek, S. Lamberts, M. Losa, A. Luger, P. Maffei, M. Marazuela, G. Mazziotti, M. Mercado, P. Mortini, S. Neggers, A.M. Pereira, S. Petersenn, M. Puig-Domingo, R. Salvatori, I. Shimon, C. Strasburger, S. Tsagarakis, A.J. van der Lely, J. Wass, M.C. Zatelli, S. Melmed, A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105, e937 (2020)

    Article  Google Scholar 

  4. P. Kamenický, G. Mazziotti, M. Lombès, A. Giustina, P. Chanson, Growth hormone, insulin-like growth Factor-1, and the kidney: pathophysiological and clinical implications. Endocr. Rev. 35, 234 (2014)

    Article  Google Scholar 

  5. S. Puglisi, M. Terzolo, Hypertension and acromegaly. Endocrinol. Metab. Clin. N. Am. 48, 779 (2019)

    Article  Google Scholar 

  6. S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27, 470 (2016)

    Article  CAS  Google Scholar 

  7. D. Niculescu, M. Purice, M. Coculescu, Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary 16, 168 (2013)

    Article  CAS  Google Scholar 

  8. O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 61 (2008)

    Article  CAS  Google Scholar 

  9. L. Katznelson, E.R. Laws, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A.H. Wass, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014)

    Article  CAS  Google Scholar 

  10. L. Maione, T. Brue, A. Beckers, B. Delemer, P. Petrossians, F. Borson-Chazot, O. Chabre, P. Fran‡ois, J. Bertherat, C. Cortet-Rudelli, P. Chanson, Changes in the management and comorbidities of acromegaly over three decades: The French acromegaly registry. Eur. J. Endocrinol. 176(5), 645–655 (2017)

    Article  CAS  Google Scholar 

  11. S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14, 552 (2018)

    Article  Google Scholar 

  12. C.R. Ku, E.Y. Choe, J.W. Hong, E.H. Kim, S.H. Park, S.H. Kim, E.J. Lee, No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study). Medicine 95, e3808 (2016)

    Article  CAS  Google Scholar 

  13. F. Bolfi, A.F. Neves, C.L. Boguszewski, V.S. Nunes-Nogueira, Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur. J. Endocrinol. 179, 59 (2018)

    Article  CAS  Google Scholar 

  14. A. Colao, L.F.S. Grasso, M. Di Cera, P. Thompson-Leduc, W.Y. Cheng, H.C. Cheung, M.S. Duh, M.P. Neary, A.M. Pedroncelli, R. Maamari, R. Pivonello, Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study. J. Endocrinol. Investig. 43(4), 529–538 (2020)

    Article  CAS  Google Scholar 

  15. J.A. Brzana, C.G. Yedinak, J.B. Delashaw, H.S. Gultelkin, D. Cook, M. Fleseriu, Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly na‹ve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary 15(4), 562–570 (2012)

    Article  CAS  Google Scholar 

  16. P. Petrossians, M.A. Tichomirowa, A. Stevenaert, D. Martin, A.F. Daly, A. Beckers, The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly. Ann. Endocrinol. 73, 190 (2012)

    Article  Google Scholar 

  17. P. Petrossians, A.F. Daly, E. Natchev, L. Maione, K. Blijdorp, M. Sahnoun-Fathallah, R. Auriemma, A.M. Diallo, A.-L. Hulting, D. Ferone, V. Hana, S. Filipponi, C. Sievers, C. Nogueira, C. Fajardo-Montañana, D. Carvalho, V. Hana, G.K. Stalla, M.-L. Jaffrain-Réa, B. Delemer, A. Colao, T. Brue, S.J.C.M.M. Neggers, S. Zacharieva, P. Chanson, A. Beckers, Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocr. Relat. Cancer 24, 505 (2017)

    Article  CAS  Google Scholar 

  18. E.O. Machado, G.F. Taboada, L.V. Neto, F.R. van Haute, L.L. Corrêa, G.A. Balarini, Y. Shrank, M. Goulart, M.R. Gadelha, Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®. Growth Horm. IGF Res. 18, 389 (2008)

    Article  CAS  Google Scholar 

  19. F.Gatto, C. Campana, F. Cocchiara, G. Corica, M. Albertelli, M. Boschetti, G. Zona, D. Criminelli, M. Giusti, D. Ferone, Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev. Endocr. Metab. Disord. 20(3), 365–381 (2019)

    Article  CAS  Google Scholar 

  20. I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667 (2004)

    Article  CAS  Google Scholar 

  21. G.A. Kanakis, A. Chrisoulidou, A. Bargiota, Z.A. Efstathiadou, L. Papanastasiou, A. Theodoropoulou, S.K.Tigas, D.A. Vassiliadi, S. Tsagarakis, M. Alevizaki, The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis. Clin. Endocrinol. 85(5), 681–688 (2016)

    Article  CAS  Google Scholar 

  22. J. D. Carmichael, V.S. Bonert, J.M. Mirocha, S. Melmed, The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J. Clin. Endocrinol. Metab. 94(2), 523–527 (2009)

    Article  CAS  Google Scholar 

  23. A.N. Paisley, K. Hayden, A. Ellis, J. Anderson, G. Wieringa, P.J. Trainer, Pegvisomant interference in GH assays results in underestimation of GH levels. Eur. J. Endocrinol. 156, 315 (2007)

    Article  CAS  Google Scholar 

  24. T.J. Reid, Z. Jin, W. Shen, C.M. Reyes-Vidal, J.C. Fernandez, J.N. Bruce, J. Kostadinov, K.D. Post, P.U. Freda, IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary 18, 808 (2015)

    Article  CAS  Google Scholar 

  25. C. Reyes-Vidal, J.C. Fernandez, J.N. Bruce, C. Crisman, I.M. Conwell, J. Kostadinov, E.B. Geer, K.D. Post, P.U. Freda, Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J. Clin. Endocrinol. Metab. 99, 4124 (2014)

    Article  CAS  Google Scholar 

  26. O. Alexopoulou, M. Bex, R. Abs, G. T’Sjoen, B. Velkeniers, D. Maiter, Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J. Clin. Endocrinol. Metab. 93, 1324 (2008)

    Article  CAS  Google Scholar 

  27. K.-C. Leung, G. Johannsson, G.M. Leong, K.K.Y. Ho, Estrogen regulation of growth hormone action. Endocr. Rev. 25, 693 (2004)

    Article  CAS  Google Scholar 

  28. M. Matta, V. Bongard, S. Grunenwald, J.-C. Maiza, A. Bennet, P. Caron, Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment. Eur. J. Endocrinol. 164, 885 (2011)

    Article  CAS  Google Scholar 

  29. M. Hage, P. Kamenicky, P. Chanson, Growth hormone response to oral glucose load: from normal to pathological conditions. Neuroendocrinology 108, 244 (2019)

    CAS  PubMed  Google Scholar 

  30. A. Pokrajac, G. Wark, A.R. Ellis, J. Wear, G.E. Wieringa, P.J. Trainer, Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin. Endocrinol. 67, 65 (2007)

    Article  CAS  Google Scholar 

  31. A.M. Arafat, M. M”hlig, M.O. Weickert, F.H. Perschel, J. Purschwitz, J. Spranger, C.J. Strasburger, C. Sch”fl, A.F.H. Pfeiffer, Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J. Clin. Endocrinol. Metab. 93(4), 1254–1262 (2008)

    Article  CAS  Google Scholar 

  32. M. Bidlingmaier, P.U. Freda, Measurement of human growth hormone by immunoassays: Current status, unsolved problems and clinical consequences. Growth Horm. IGF Res. 20, 19 (2010)

    Article  CAS  Google Scholar 

  33. J.O.L. Jørgensen, M. Krag, N. Jessen, H. Nørrelund, E.T. Vestergaard, N. Møller, J.S. Christiansen, Growth Hormone and Glucose Homeostasis. Horm. Res. Paediatr. 62, 51 (2004)

    Article  Google Scholar 

  34. J. Dal, M. Klose, A. Heck, M. Andersen, C. Kistorp, E.H. Nielsen, J. Bollerslev, U. Feldt-Rasmussen, J.O.L. Jørgensen, Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. Eur. J. Endocrinol. 178, 65 (2018)

    Article  CAS  Google Scholar 

  35. M. Christiansen Arlien-Søborg, C. Trolle, E. Alvarson, A. Bæk, J. Dal, J.O.L. Jørgensen, Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. Endocrine 56, 589 (2017)

    Article  Google Scholar 

  36. L. Katznelson, J.L.D. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American Association of Clinical Endocrinologists, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr. Pract. 17(Supplement 4), 1–44 (2011)

    Article  Google Scholar 

  37. L. Maione, P. Chanson, National acromegaly registries. Best Pract. Res. Clin. Endocrinol. Metab. 33, 101264 (2019)

    Article  Google Scholar 

Download references

Acknowledgements

This work was funded by an unrestricted grant from IPSEN to Albert Beckers.

Author information

Authors and Affiliations

  1. Aix Marseille Univ, APHM, INSERM, MMG, Service d’endocrinologie, Hôpital de la Conception, Marseille, France

    V. Amodru, F. Castinetti, T. Brue & T. Cuny

  2. Department of Endocrinology, CHU de Liège, Université de Liege, Liège, Belgium

    P. Petrossians & A. Beckers

  3. Dipartimento Di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, University “Federico II”, Naples, Italy

    A. Colao & R. Pivonello

  4. Service d’endocrinologie, CHU de Reims, Reims, France

    B. Delemer & B. Decoudier

  5. Service d’Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France

    L. Maione, P. Kamenicky & P. Chanson

  6. Section of Endocrinology Department of Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

    S.J.C.M.M. Neggers

  7. Third Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

    V. Hana

  8. Department of Endocrinology Diabetes and Metabolism, Centro Hospitalar Universitário S. João, Faculty of Medicine, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal

    D. Carvalho

Authors
  1. V. Amodru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Petrossians
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Delemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Maione
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S.J.C.M.M. Neggers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Decoudier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Kamenicky
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Castinetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V. Hana
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D. Carvalho
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T. Brue
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Beckers
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P. Chanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. T. Cuny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Cuny.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amodru, V., Petrossians, P., Colao, A. et al. Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database. Endocrine 70, 134–142 (2020). https://doi.org/10.1007/s12020-020-02387-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-020-02387-1

Keywords

Search

Navigation